Table 3.
Pooled prevalence of the 2304 18F-FDG TIs in the six Bethesda categories
| TBS category | Prevalence (%), 95% CI | I2 (%) | Egger test (p) |
|---|---|---|---|
| I (ND) | 10, 6–14 | 86.0 | 0.30 |
| II (B) | 45, 37–53 | 92.7 | 0.15 |
| III (AUS/FLUS) | 8, 3–13 | 94.6 | 0.11 |
| IV (FN/SFN) | 8, 5–12 | 88.2 | 0.001 |
| V (SFM) | 6, 4–9 | 69.8 | 0.03 |
| VI (M) | 19, 13–25 | 91.6 | 0.86 |
TBS the Bethesda system for reporting thyroid cytopathology, ND nondiagnostic, B benign, AUS/FLUS atypia of undetermined significance/follicular lesion of undetermined significance, FN/SFN follicular neoplasms/suspicious for follicular neoplasms, M malignant, SFM suspicious for malignancy, CI confidence interval, I2 inconsistency